A recent partnership to address the challenge of monitoring adherence in ophthalmic clinical trials was formed between Aptar Pharma and Kali Care. Here, Sina Fateh, MD, founder and CEO of Kali Care and Sai Shankar, director, Business Development — Connected Devices, Aptar Pharma, discuss this alliance further.
Patient adherence to therapy is a long-standing issue across the full spectrum of the healthcare industry. According to the World Health Organisation a mere 50% of patients in developed countries with chronic disease are adherent to their therapeutic regimen.1 This lack in maintaining a prescribed therapeutic schedule leads to medicines being less effective than anticipated and a significant increase in financial burden on national healthcare systems.